The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Official Title: MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Study ID: NCT04632992
Brief Summary: This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers. Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Alaska Oncology and Hematology, Anchorage, Alaska, United States
Arizona Clinical Research Ctr, Oro Valley, Arizona, United States
Genesis Cancer Center, Hot Springs, Arkansas, United States
California Cancer Associates for Research and Excellence - Encinitas, Encinitas, California, United States
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
Pacific Cancer Care - Monterey, Monterey, California, United States
Kaiser Permanente - Sacramento Medical Center and Medical Offices, Sacramento, California, United States
Kaiser Permanente - San Francisco Medical Center, San Francisco, California, United States
Kaiser Permanente - San Jose Medical Center, San Jose, California, United States
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States
Kaiser Permanente - Santa Clara, Santa Clara, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
Kaiser Permanente - South San Francisco, South San Francisco, California, United States
Kaiser Permanente Medical Ctr, Vallejo, California, United States
Ventura County Hematology Oncology Specialists, Ventura, California, United States
K. Permanente - Walnut Creek, Walnut Creek, California, United States
Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
Florida Cancer Specialists - NORTH - SCRI - PPDS, Saint Petersburg, Florida, United States
Florida Cancer Specialists - PAN - SCRI - PPDS, Tallahassee, Florida, United States
Florida Cancer Specialists - EAST - SCRI - PPDS, West Palm Beach, Florida, United States
St Luke?s Cancer Institute, Boise, Idaho, United States
Hematology and Oncology Clinic, Baton Rouge, Louisiana, United States
Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore, Maryland, United States
Ascension St. John Hospital, Detroit, Michigan, United States
Frontier Cancer Center and Blood Institute, Billings, Montana, United States
Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States
New Jersey Hematology Oncology Associates LLC, Brick, New Jersey, United States
Astera Cancer Care East Brunswick, East Brunswick, New Jersey, United States
Eastchester Center for Cancer Care, Bronx, New York, United States
Central Park Hematology and Oncology, New York, New York, United States
New York Cancer & Blood Specialists, Shirley, New York, United States
Messino Cancer Centers, Asheville, North Carolina, United States
Gabrail Cancer Center, Canton, Ohio, United States
Tri County Hematologyoncology, Canton, Ohio, United States
SCRI Mark H. Zangmeister Center, Columbus, Ohio, United States
Kaiser Permanente Center For Health Research, Portland, Oregon, United States
SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
The West Clinic, PC dba West Cancer Center, Memphis, Tennessee, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
The Center for Cancer and Blood Disorders - PPDS, Fort Worth, Texas, United States
Mays Cancer Center at UT Health San Antonio MD Anderson Cancer, San Antonio, Texas, United States
Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States
Northwest Medical Specialties B, Federal Way, Washington, United States
Name: Clinical Trials
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR